Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 6.7543
1.42 %
$ 3.93 M
Market Cap
-0.59
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart ACON
FINANCIALS
Balance Sheet
Aclarion, Inc.
| Current Assets | 824 K |
| Cash & Short-Term Investments | 454 K |
| Receivables | 18.3 K |
| Other Current Assets | 352 K |
| Non-Current Assets | 1.3 M |
| Long-Term Investments | 0 |
| PP&E | 5.5 K |
| Other Non-Current Assets | 1.29 M |
| Current Liabilities | 1.15 M |
| Accounts Payable | 532 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 622 K |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Aclarion, Inc.
| Revenue | 45.7 K |
| Cost Of Revenue | 130 K |
| Gross Profit | -84 K |
| Operating Expenses | 5.43 M |
| Operating Income | -5.51 M |
| Other Expenses | 1.48 M |
| Net Income | -6.99 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aclarion, Inc.
| Net Income | -6.99 M |
| Depreciation & Amortization | 193 K |
| Capital Expenditures | -322 K |
| Stock-Based Compensation | 287 K |
| Change in Working Capital | -564 K |
| Others | 1.39 M |
| Free Cash Flow | -5.59 M |
Wall Street Analysts Price Targets
Aclarion, Inc.
ACON has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ACON does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aclarion, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Keck Medical Center of USC as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
globenewswire.com
- 1 month ago
Aclarion Announces Texas Back Institute as New CLARITY Trial Site
Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of the Texas Back Institute (TBI) as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial site.
globenewswire.com
- 1 month ago
Aclarion Welcomes Advocate Health as CLARITY Trial Site
Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Advocate Aurora Research Institute, part of Advocate Health, as a CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) site.
globenewswire.com
- 1 month ago
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
Expands access to first customer using Philips MR Spectroscopy (MRS), demonstrating ease of Nociscan integration across multiple MRS platforms Nociscan now commercially available at 17 sites covering eight states and four countries BROOMFIELD, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, LA.
globenewswire.com
- 1 month ago
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025
BROOMFIELD, Colo., April 23, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.
globenewswire.com
- 1 month ago
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a peer-reviewed article in Clinicoeconomics and Outcomes Research titled "The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.
globenewswire.com
- 1 month ago
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub
BROOMFIELD, Colo., April 09, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.
globenewswire.com
- 2 months ago
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica Broomfield, CO, April 2, 2025 – PRISM MediaWire – Aclarion, Inc.
prismmediawire.com
- 2 months ago
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan product is now available in Santa Monica at Medical Imaging Center of Southern California (MICSC).
globenewswire.com
- 2 months ago
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update on its strengthened positioning following the successful execution of strategic initiatives in Q1 2025.
globenewswire.com
- 2 months ago
Aclarion Provides Shareholder Update
BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review.
globenewswire.com
- 3 months ago
Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey.
globenewswire.com
- 3 months ago
8. Profile
Summary
Aclarion, Inc. ACON
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 3.93 M
Dividend Yield
0.02%
Description
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Contact
951 Mariners Island Boulevard, Broomfield, CA, 94404
https://www.aclarion.com
IPO
Date
April 22, 2022
Employees
5
Officers
Mr. Ryan Bond
Chief Strategy Officer
Dr. Jeffrey John Thramann M.D.
Executive Chairman
Mr. Brent Ness
Chief Executive Officer, President & Director
Mr. John Lorbiecki
Chief Financial Officer